Cargando…
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment,...
Autores principales: | Akamatsu, Hiroaki, Ninomiya, Kiichiro, Kenmotsu, Hirotsugu, Morise, Masahiro, Daga, Haruko, Goto, Yasushi, Kozuki, Toshiyuki, Miura, Satoru, Sasaki, Takaaki, Tamiya, Akihiro, Teraoka, Shunsuke, Tsubata, Yukari, Yoshioka, Hiroshige, Hattori, Yoshihiro, Imamura, Chiyo K., Katsuya, Yuki, Matsui, Reiko, Minegishi, Yuji, Mizugaki, Hidenori, Nosaki, Kaname, Okuma, Yusuke, Sakamoto, Setsuko, Sone, Takashi, Tanaka, Kentaro, Umemura, Shigeki, Yamanaka, Takeharu, Amano, Shinsuke, Hasegawa, Kazuo, Morita, Satoshi, Nakajima, Kazuko, Maemondo, Makoto, Seto, Takashi, Yamamoto, Nobuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545178/ https://www.ncbi.nlm.nih.gov/pubmed/31049758 http://dx.doi.org/10.1007/s10147-019-01431-z |
Ejemplares similares
-
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
por: Ninomiya, Kiichiro, et al.
Publicado: (2020) -
The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer
por: Nosaki, Kaname, et al.
Publicado: (2015) -
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
por: Seto, Takashi, et al.
Publicado: (2022) -
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
por: Yamamoto, Noboru, et al.
Publicado: (2016) -
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
por: Shimokawa, Mototsugu, et al.
Publicado: (2020)